Skip to main content

Table 5 Aminoglycoside MICs in relation to the presence of aminoglycoside-modifying enzyme gene combination (excluding the presence of ant(3΄)-I and aph(3′)-I

From: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance

AME gene(s) No (%) of isolates Expected resistance phenotypea Amikacin Gentamicin Tobramycin Plazomicin
Range MIC50/90 % NS Range MIC50/90 % NS Range MIC50/90 % NS Range MIC50/90 % NSb
None 28 (9.3) Susceptible 1-8 2/8 0.0 0.25-4 1/2 7.1 0.25-8 1/4 10.7 ≤0.125-4 0.5/4 14.3
aac(6΄)-Ib 168 (66) A,T,N 2-256 32/128 91.7 0.25- > 256 2/16 47.0 2- > 256 32/64 99.4 ≤0.125-8 0.5/2 4.2
aac(3΄)-IIa 6 (2.0) G,T,N 2-8   0.0 64-256   100.0 8-64   100.0 ≤0.125-1   0.0
aac(6΄)-Ib + aac(3΄)-IIa 64 (21.3) A,G,T,N 4-256 32/64 90.6 1- > 256 64/256 81.3 4- > 256 64/128 100.0 ≤0.125-8 0.5/1 4.7
aac(6′)-Ib + aph(3′)-VI 6 (2.0) A,T,N 32-128   100.0 2-64   66.7% 4-256   100.0 0.25-4   33.3
aac(6′)-Ib + aac(3′)-IIa + aph(3′)-VI 3 (1.0) A,G,T,N 32-256   100.0 128- > 256   100.0 32-256   100.0 0.25-1   0.0
aac(6′)-Ib + ant(2′)-Ia 2 (0.7) A,G,T,N 16-128   100.0 8   100.0 32   100.0 0.25-2   0.0
rmtB or armA ± any AME 23 (7.7) A,G,T,N,P > 256 > 256 100 128- > 256 > 256 100.0 64- > 256 > 256 100.0 64- > 256 > 256 100.0
  1. a A, resistance to amikacin; G, resistance to gentamicin; T, resistance to tobramycin; N, resistance to netilmicin; P, resistance to plazomicin
  2. b According the recently approved FDA breakpoint